We demonstrated that RB1 knockdown in abemaciclib-treated breast cancer cells resulted in reduced lysosomal biogenesis, accompanied by decreased sensitivity to lysosomotropic agent-induced cell death triggered by abemaciclib. Here, RB1 is linked to breast carcinoma.